{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:06:41Z","timestamp":1791245201762,"version":"4.1.0"},"reference-count":34,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,28]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Patients with chronic lymphocytic leukemia (CLL) often experience infections due to immune suppression and\/or dysregulation. Hypogammaglobulinemia is a key contributor to immunosuppression in CLL, and immunoglobulin replacement therapy (IgRT) is commonly given to prevent infections. However, the benefit of IgRT in preventing serious infections in CLL remains unclear. This study aimed to describe IgRT treatment patterns in a large, real-world cohort of patients with CLL, and explore the association between IgRT and serious infections. We conducted a retrospective longitudinal study of linked hospital data, including 6217 patients with CLL between 2008 and 2022 in Victoria, Australia. Kaplan-Meier survival analyses were performed to estimate survival, infection incidence, and IgRT use. Cox survival analyses explored associations between infections and IgRT in patients receiving regular prophylactic IgRT. Over the 14-year follow-up, the monthly proportion of patients experiencing serious infections doubled, while the proportion of patients receiving any IgRT quadrupled. The median time to death from CLL diagnosis was 10 years, and patients with serious infections had a higher mortality rate (0.090 [95% confidence interval (CI), 0.074-0.110]) vs those without (0.008 [95% CI, 0.007-0.009]). In total, 753 patients (12.1%) received IgRT, and 524 (8.4%) received IgRT regularly. In patients who received regular IgRT, infection incidence was higher during periods of IgRT (0.056 [95% CI, 0.052-0.060]) compared with periods without IgRT (0.038 [95% CI, 0.035-0.042]). Serious infections were associated with not only IgRT initiation and reinitiation, but also cessation. Further research is needed to evaluate the causal relationship between IgRT and infections in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025015867","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T13:52:01Z","timestamp":1753969921000},"page":"5367-5377","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":10,"title":["Immunoglobulin use, survival, and infection outcomes in patients with chronic lymphocytic leukemia"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1206-5392","authenticated-orcid":false,"given":"Sara","family":"Carrillo de Albornoz","sequence":"first","affiliation":[{"name":"1Transfusion Research Unit, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia"},{"name":"2Centre for Health Economics, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[{"name":"2Centre for Health Economics, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9336-5735","authenticated-orcid":false,"given":"Rainier","family":"Arnolda","sequence":"additional","affiliation":[{"name":"2Centre for Health Economics, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2332-8186","authenticated-orcid":false,"given":"Aleece","family":"MacPhail","sequence":"additional","affiliation":[{"name":"1Transfusion Research Unit, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia"},{"name":"3Department of Infectious Diseases, Monash Health, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Irving","sequence":"additional","affiliation":[{"name":"1Transfusion Research Unit, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia"},{"name":"2Centre for Health Economics, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8295-7559","authenticated-orcid":false,"given":"Alisa M.","family":"Higgins","sequence":"additional","affiliation":[{"name":"6Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7527-2340","authenticated-orcid":false,"given":"Erica M.","family":"Wood","sequence":"additional","affiliation":[{"name":"1Transfusion Research Unit, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia"},{"name":"4Monash Haematology, Monash Health, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9698-7185","authenticated-orcid":false,"given":"Zoe K.","family":"McQuilten","sequence":"additional","affiliation":[{"name":"1Transfusion Research Unit, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia"},{"name":"4Monash Haematology, Monash Health, Melbourne, Australia"},{"name":"5Department of Haematology, Alfred Health, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3882-2531","authenticated-orcid":false,"given":"Dennis","family":"Petrie","sequence":"additional","affiliation":[{"name":"2Centre for Health Economics, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,10,20]]},"reference":[{"key":"2025102809214768100_bib1","unstructured":"Centers for Disease Control and Prevention\n          . Hematologic cancer incidence, survival, and prevalence. Accessed 7 October 2024. https:\/\/stacks.cdc.gov\/view\/cdc\/124457."},{"key":"2025102809214768100_bib2","unstructured":"Australian Institute of Health and Welfare\n          . Cancer data in Australia. Accessed 4 October 2024. https:\/\/www.aihw.gov.au\/reports\/cancer\/cancer-data-in-australia\/contents\/summary-dashboard."},{"issue":"6","key":"2025102809214768100_bib3","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/ejh.13754","article-title":"Immunoglobulin replacement therapy in chronic lymphocytic leukaemia patients with hypogammaglobulinaemia and infection","volume":"108","author":"Keegan","year":"2022","journal-title":"Eur J Haematol"},{"key":"2025102809214768100_bib4","doi-asserted-by":"crossref","first-page":"1062376","DOI":"10.3389\/fimmu.2023.1062376","article-title":"Should treatment of hypogammaglobulinemia with immunoglobulin replacement therapy (IgRT) become standard of care in patients with chronic lymphocytic leukemia?","volume":"14","author":"Noto","year":"2023","journal-title":"Front Immunol"},{"issue":"5","key":"2025102809214768100_bib5","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1007\/s00277-024-05625-y","article-title":"Prediction of severe infections in chronic lymphocytic leukemia: a simple risk score to stratify patients at diagnosis","volume":"103","author":"Murru","year":"2024","journal-title":"Ann Hematol"},{"issue":"5","key":"2025102809214768100_bib6","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.jaci.2022.01.025","article-title":"Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: a Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees","volume":"149","author":"Otani","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"17","key":"2025102809214768100_bib7","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1002\/cncr.29438","article-title":"Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: natural history, clinical correlates, and outcomes","volume":"121","author":"Parikh","year":"2015","journal-title":"Cancer"},{"key":"2025102809214768100_bib8","doi-asserted-by":"crossref","first-page":"1135812","DOI":"10.3389\/fonc.2023.1135812","article-title":"An updated perspective on immunoglobulin replacement in chronic lymphocytic leukaemia in the era of targeted therapies. Review","volume":"13","author":"Khan","year":"2023","journal-title":"Front Oncol"},{"issue":"3","key":"2025102809214768100_bib9","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s10875-014-9995-5","article-title":"Antibody deficiency secondary to chronic lymphocytic leukemia: should patients be treated with prophylactic replacement immunoglobulin?","volume":"34","author":"Dhalla","year":"2014","journal-title":"J Clin Immunol"},{"issue":"6","key":"2025102809214768100_bib10","first-page":"5187","article-title":"Immunoglobulin substitution in patients with secondary antibody deficiency in chronic lymphocytic leukemia and multiple myeloma: a representative analysis of guideline adherence and infections","volume":"30","author":"Link","year":"2022","journal-title":"Support Care Cancer"},{"issue":"1","key":"2025102809214768100_bib11","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3747\/co.23.2810","article-title":"A Canadian perspective on the use of immunoglobulin therapy to reduce infectious complications in chronic lymphocytic leukemia","volume":"23","author":"Lachance","year":"2016","journal-title":"Curr Oncol"},{"issue":"7","key":"2025102809214768100_bib12","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.3109\/10428194.2016.1142082","article-title":"Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia is a predictor of early death","volume":"57","author":"Andersen","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2025102809214768100_bib13","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/bloodadvances.2022008073","article-title":"Interventions to reduce infections in patients with hematological malignancies: a systematic review and meta-analysis","volume":"7","author":"Chai","year":"2023","journal-title":"Blood Adv"},{"key":"2025102809214768100_bib14","unstructured":"UK Department of Health\n          . Clinical guidelines for immunoglobulin use, update to 2nd edition. Accessed 11 August 2025. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/216671\/dh_131107.pdf."},{"key":"2025102809214768100_bib15","unstructured":"BloodStar\n          . Criteria for clinical use of immunoglobulin in Australia: acquired hypogammaglobulinaemia secondary to haematological malignancies, or post-haemopoietic stem cell transplantation (HSCT). Accessed 7 April 2022. https:\/\/www.criteria.blood.gov.au\/MedicalCondition\/View\/2621."},{"key":"2025102809214768100_bib16","unstructured":"European Medicines Agency\n          . Guideline on core SmPC for human normal immunoglobulin for intravenous administration (IVIg). Accessed 11 August 2025. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-core-smpc-human-normal-immunoglobulin-intravenous-administration-ivig-rev-5_en.pdf."},{"issue":"3","key":"2025102809214768100_bib17","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/imj.14082","article-title":"Managing hypogammaglobulinaemia secondary to haematological malignancies in Australia and New Zealand: a clinician survey","volume":"49","author":"Wong","year":"2019","journal-title":"Intern Med J"},{"issue":"6","key":"2025102809214768100_bib18","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/ejh.13223","article-title":"Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies","volume":"102","author":"Na","year":"2019","journal-title":"Eur J Haematol"},{"issue":"19","key":"2025102809214768100_bib19","doi-asserted-by":"crossref","first-page":"6356","DOI":"10.3390\/jcm12196356","article-title":"Current approach in the management of secondary immunodeficiency in patients with hematological malignancies: Spanish expert consensus recommendations","volume":"12","author":"Boqu\u00e9","year":"2023","journal-title":"J Clin Med"},{"issue":"9","key":"2025102809214768100_bib20","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1182\/bloodadvances.2023012047","article-title":"Economic evaluation: immunoglobulin vs prophylactic antibiotics in hypogammaglobulinemia and hematological malignancies","volume":"8","author":"Carrillo de Albornoz","year":"2024","journal-title":"Blood Adv"},{"key":"2025102809214768100_bib21","unstructured":"Independent Health and Aged Care Pricing Authority\n          . ICD-10-AM\/ACHI\/ACS Eleventh edition. Accessed 5 January 2024. https:\/\/www.ihacpa.gov.au\/resources\/icd-10-amachiacs-eleventh-edition."},{"key":"2025102809214768100_bib22","unstructured":"Victorian Agency for Health Information\n          . Data linkage methodology. Accessed 1 May 2025. https:\/\/vahi.vic.gov.au\/ourwork\/data-linkage\/data-linkage-methodology."},{"issue":"1","key":"2025102809214768100_bib23","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jclinepi.2014.09.017","article-title":"The ICD-10 Charlson Comorbidity Index predicted mortality but not resource utilization following hip fracture","volume":"68","author":"Toson","year":"2015","journal-title":"J Clin Epidemiol"},{"key":"2025102809214768100_bib24","unstructured":"National Blood Authority\n          . National report on the issue and use of immunoglobulin (Ig) annual report 2021-2022. Accessed 11 August 2025. https:\/\/www.blood.gov.au\/report-issue-and-use-immunoglobulin."},{"key":"2025102809214768100_bib25","unstructured":"Victorian Department of Health\n          . Subcutaneous immunoglobulin (SCIg) access program. Accessed 8 November 2024. https:\/\/www.health.vic.gov.au\/patient-care\/subcutaneous-immunoglobulin-scig-access-program."},{"issue":"2","key":"2025102809214768100_bib26","first-page":"61","article-title":"Performance of hospital administrative data for detection of sepsis in Australia: the sepsis coding and documentation (SECOND) study","volume":"53","author":"Duke","year":"2024","journal-title":"Health Inf Manag"},{"key":"2025102809214768100_bib27","unstructured":"Wang\n              JL\n            \n          . Smoothing Hazard Rates. Wiley StatsRef: Statistics Reference Online [Internet]. Accessed 11 August 2025. https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/9781118445112.stat06057."},{"issue":"4","key":"2025102809214768100_bib28","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1214\/aos\/1176345976","article-title":"Cox\u2019s regression model for counting processes: a large sample study","volume":"10","author":"Andersen","year":"1982","journal-title":"Ann Statist"},{"issue":"5","key":"2025102809214768100_bib29","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1093\/aje\/kwx133","article-title":"Prediction of multiple recurrent events: a comparison of extended Cox models in bladder cancer","volume":"186","author":"Smedinga","year":"2017","journal-title":"Am J Epidemiol"},{"key":"2025102809214768100_bib30","unstructured":"National Blood Authority\n          . Immunoglobulin Governance National Policy: access to government-funded immunoglobulin products in Australia. Accessed 8 November 2024. https:\/\/www.blood.gov.au\/sites\/default\/files\/documents\/immunoglobulin-governance-national-policy-2019.pdf."},{"issue":"16","key":"2025102809214768100_bib31","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1182\/bloodadvances.2024013073","article-title":"IgG testing, immunoglobulin replacement therapy, and infection outcomes in patients with CLL or NHL: real-world evidence","volume":"8","author":"Soumerai","year":"2024","journal-title":"Blood Adv"},{"issue":"11","key":"2025102809214768100_bib32","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1007\/s00277-024-05984-6","article-title":"Treatment patterns and burden of infection in patients with chronic lymphocytic leukemia and secondary immunodeficiency: a retrospective database study","volume":"103","author":"Siffel","year":"2024","journal-title":"Ann Hematol"},{"key":"2025102809214768100_bib33","unstructured":"National Blood Authority\n          . Report on the issue and use of immunoglobulin: from 2014-15 to 2021-22. Accessed 3 January 2024. https:\/\/www.blood.gov.au\/report-issue-and-use-immunoglobulin."},{"key":"2025102809214768100_bib34","article-title":"Evaluate and develop options to improve access to subcutaneous immunoglobulin (SCIg)","author":"National Blood Authority","year":"2023","journal-title":"Final Rep"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/20\/5367\/2417684\/blooda_adv-2025-015867-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/20\/5367\/2417684\/blooda_adv-2025-015867-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T13:22:10Z","timestamp":1761657730000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/20\/5367\/546406\/Immunoglobulin-use-survival-and-infection-outcomes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,20]]},"references-count":34,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2025,10,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025015867","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10,28]]},"published":{"date-parts":[[2025,10,20]]}}}